Albireo to Present at Upcoming Jefferies and William Blair Virtual Investor Conferences
May 26, 2021 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief...
Albireo erhält eine positive CHMP-Beurteilung für Odevixibat zur Behandlung der progressiven familiären intrahepatischen Cholestase (PFIC)
May 21, 2021 08:35 ET
|
Albireo Pharma, Inc.
– Odevixibat verfügt über das Potenzial, das erste zugelassene Arzneimittel für die Behandlung aller Formen von PFIC zu werden – – Die Beurteilung des CHMP basiert auf den PEDFIC-Phase-3-Studien – ...
Albireo Receives Positive CHMP Opinion for Bylvay™ (odevixibat) for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)
May 21, 2021 08:35 ET
|
Albireo Pharma, Inc.
– Bylvay has the potential to become first approved drug to treat all forms of PFIC – – CHMP opinion is based on the PEDFIC Phase 3 studies – – PEDFIC 1 met the bile acid (P=0.003) and pruritus...
Albireo to Showcase New Data at 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition
May 19, 2021 08:30 ET
|
Albireo Pharma, Inc.
- PEDFIC 1 and PEDFIC 2 Phase 3 data presentations on long-term safety, tolerability, and improved outcomes for patients with PFIC - - Data showing long-term treatment benefits of...
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 07, 2021 16:01 ET
|
Albireo Pharma, Inc.
BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of...
Albireo Reports Q1 Financial Results and Business Update
May 06, 2021 08:30 ET
|
Albireo Pharma, Inc.
– BylvayTM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU– – Completed global commercial agreements for two key top ten markets – – ASSERT & BOLD Phase 3...
Albireo to Report First Quarter 2021 Financial Results on May 6
April 29, 2021 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that...
Albireo Expands Leadership with Joan Connolly as Chief Technology Officer
April 13, 2021 08:30 ET
|
Albireo Pharma, Inc.
– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs – – Deep experience spanning drug...
Albireo to Participate in the Needham 20th Annual Virtual Healthcare Conference
April 06, 2021 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, April 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in...
Albireo Announces First Patients Dosed in Two New Studies
March 25, 2021 08:30 ET
|
Albireo Pharma, Inc.
– Dosed first patients in Phase 1 study with new product candidate A3907 – – First patient dosed in ASSERT global Phase 3 study of odevixibat for Alagille syndrome – – EMA & FDA reviewing...